Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20042215 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2SLC22A2SLC47A1MAPT | |
| SCHEMBL20042213 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2SLC22A2SLC47A1MAPT | |
| SCHEMBL20042201 | 0.86 | — | — | |
| SCHEMBL20042199 | 0.86 | — | — | |
| SCHEMBL20042198 | 0.86 | — | — | |
| SCHEMBL21401948 | 0.81 | SLC22A2 (0.36) | SMN1; SMN2SLC22A2SLC47A1MAPT | |
| SCHEMBL20002011 | 0.81 | SLC22A2 (0.36) | SMN1; SMN2SLC22A2SLC47A1MAPT | |
| SCHEMBL2239665 | 0.81 | SLC22A2 (0.36) | SMN1; SMN2SLC22A2SLC47A1MAPT | |
| SCHEMBL20042203 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC22A2SLC47A1MAPT | |
| SCHEMBL20042205 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2SLC22A2SLC47A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099939-A1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION AND INDICATIONS THEREFOR | IDO1, TDO2, IDO2 | SMN1; SMN2 2220/4885SLC22A2 1286/4885SLC47A1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.